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MI, USAA B S T R A C TBackground: Radiofrequency ablation (RFA) is an established but
expensive treatment alternative for many forms of supraventricular
tachycardia (SVT). Currently, no studies exist on the cost-
effectiveness of RFA compared with that of medical treatment (MT)
in adult Latin American population. Methods: Between 2007 and
2012, we identiﬁed 103 adults who underwent RFA for SVT in the
National Unit of Cardiovascular Surgery (Unidad Nacional de Cirugía
Cardiovascular [UNICAR]) in Guatemala. A decision tree was devel-
oped with all clinical outcome parameter estimates obtained from the
Adult Electrophysiology Clinic. Cost data were obtained from UNI-
CAR’s administration. A cost-effectiveness analysis that evaluated
costs and quality-adjusted life-years to compare interventions in
terms of their incremental cost-effectiveness ratios was conducted.
Results: The ﬁrst RFA had an 83% success rate, and a cumulative
success rate of 94% was achieved with a second. The cost of the RFA
procedure itself was $5411. RFA gained 1.46 quality-adjusted life-yearsee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.06.002
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llas TX 75203.and saved $7993 compared with MT for patients with SVT. This
demonstrates that in Guatemala, RFA dominates MT in the
management of SVT. Using assumptions based largely on the
outcomes in UNICAR, we found that RFA is highly cost-effective.
This is a consistent ﬁnding, even after varying assumptions about
efﬁcacy, complication rates, and quality of life. Conclusions: RFA
dominates MT by improving quality of life and reducing expenditures
when used to treat patients with severe symptoms of SVT in
Guatemala. The robustness of these ﬁnding to variations in parameter
assumptions suggests that these ﬁndings may hold in other similar
settings.
Keywords: cost-effectiveness, quality-adjusted life year, radiofrequency
ablation, supraventricular tachycardia.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Supraventricular tachycardias (SVTs) are a group of common
rhythm disturbances. They represent the most common class of
heart rhythm disorders requiring medical attention. Radiofre-
quency ablation (RFA) is an established but expensive treatment
alternative for many forms of SVT [1]. Most cases of SVT are not
life-threatening (with the exception of tachycardias for the
accessory pathway such as Wolf-Parkinson-White) [2]. However,
patients with severe symptoms have multiple episodes per year
that require urgent medical intervention to terminate the
arrhythmia; these episodes substantially diminish quality of life;
therefore, the goal of therapy is to improve the patients’ quality
of life [3].
Costs for RFA in the pediatric population in Guatemala in 2005
were calculated to be US $1405 for a ﬁrst ablation and $1668 for asecond in event of recurrence. The estimated cost of these
ablations was demonstrated to be equal to that of continued
medical therapy (MT) after 5.1 years and 3.4 times less than that
of MT after 20 years [4]. Nevertheless, currently no studies exist
on an adult Latin American population.
Guatemala is a lower- to middle-income country with a gross
domestic product (GDP) of $3478 per capita in 2013 [5]. The
National Unit of Cardiovascular Surgery (Unidad Nacional de
Cirugía Cardiovascular [UNICAR]) is the only public center with
access to an advanced electrophysiology program in Guatemala,
covering a population of 15,073,375 inhabitants [6]. Although no
published data about the incidence of SVT in Guatemala exist, in
an era in which high-tech therapies are proliferating, it is
necessary to examine whether these expenses are reasonable,
especially in centers and countries with limited resources and
different cultural acceptance [4].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Unidad Nacional de Cirugía Cardiovascular or any company per
dicine Department, Methodist Dallas Medical Center, 1441 North
Table 1 – Characteristics and outcomes of patients
undergoing RFA in UNICAR from 2007 to 2012.
Characteristic Value
Age at ablation (y), mean  SD 35.78  14.51
Clinical indication, n (%)
SVT 48 (46.60)
WPW þ SVT 47 (45.63)
Pre-exitation 5 (4.85)
Auricular ﬂutter 2 (1.94)
Unifocal auricular tachycardia 1 (0.97)
Number of visits pre-RFA, mean  SD 2.44  1.01
MT pre-RFA, n (%)
No treatment 29 (28.15)
One drug 63 (61.20)
Propafenone 36 (34.95)
Beta blocker 14 (13.60)
Amiodarone 6 (5.83)
Verapamil 5 (4.85)
Digoxin 1 (0.97)
Sotalol 1 (0.97)
Two drugs 11 (10.70)
Propafenone þ amiodarone 4 (3.88)
Propafenone þ beta blocker 4 (3.88)
Propafenone þ digoxine 1 (0.97)
Propafenone þ magnesium 1 (0.97)
Propafenone þ verapamil 1 (0.97)
Hospital stay (d), mean  SD 3.24  0.31
Patients who required ICU, n (%) 5 (4.85)
ICU stay (d), mean  SD 2.6  0.87
Postablation diagnosis, n (%)
WPW 45 (43.69)
Classic AVRNT 23 (22.33)
Hidden accessory pathway 11 (10.68)
Double physiology of AV node without
tachycardia induction
10 (9.71)
AVRNT þ AFib 3 (2.91)
Atypical AVRNT 2 (1.94)
Atrial ﬂutter 2 (1.94)
Preexitation syndrome þ AFib 2 (1.94)
Epicardic accessory pathway 2 (1.94)
AFib 1 (0.97)
Left and right auricular reentry 1 (0.97)
Auricular tachycardia 1 (0.97)
Outcomes, n (%)
RFA initially successful 86 (83.50)
RFA failed 17 (16.50)
MT 5 (4.86)
Second RFA 12 (11.64)
Success after second ablation 97 (94.17)
Complications, n (%) 2 (1.94)
Hemodynamic instability 1 (0.97)
Major bleeding 0 (0.00)
Vascular injury 1 (0.97)
Complete heart block 0 (0.00)
Death 0 (0.00)
Visits post-RFA, mean  SD 2.26  1.08
MT post-RFA, n (%)
No treatment 41 (39.81)
Aspirin 30 (29.13)
Propafenone 17 (15.60)
Beta blocker 6 (5.80)
Aspirin þ clopidogrel 2 (1.94)
Amiodarone 2 (1.94)
Propafenone þ beta blocker 2 (1.94)
continued on next page
Table 1 – continued
Characteristic Value
Amiodarone þ beta blocker 1 (0.97)
Sotalol 1 (0.97)
Propafenone þ digoxin 1 (0.97)
AFib, atrial ﬁbrillation; AV, atrioventricular; AVRNT; atrioventricu-
lar reentry nodal tachycardia; ICU; intensive care unit; MT, medical
treatment; RFA, radiofrequency ablation; SVT, supraventricular
tachycardia; UNICAR, Unidad Nacional de Cirugía Cardiovascular;
WPW, Wolf-Parkinson-White.
* Lesion to the internal jugular vein.
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that in patients with SVT who are highly symptomatic or have
monthly episodes of arrhythmia, RFA is more effective and less
expensive than long-term drug therapy. In addition, ablation
improved quality-adjusted life-years (QALYs) by 3.1 years and
reduced expenses by US $27,900. However, these studies are
several decades old and focused on the United States. Although
the procedure is highly effective, with success rates more than
90% in some centers, it has a moderate risk of complications and
is relatively expensive [3,7,8].
A limitation of these analyses is that data were gathered from
major centers of reference, with highly specialized success rates
that often do not represent the less experienced centers, which
may differ in various degrees. Furthermore, the analysis was
carried out considering only one treatment drug, when in clinical
practice physicians usually prescribe various drugs with prices
very different from each other [7,8]. Therefore, the objectives of
this study were to demonstrate the effectiveness of RFA for SVT
in an adult population in Guatemala and to analyze its cost-
effectiveness when compared with conventional MT.Methods
Local Health Outcomes for RFA
We performed a retrospective study in which we reviewed the
charts of adult patients (older than 18 years) with SVT who live in
Guatemala and had undergone an electrophysiology study and
RFA from January 2007 to April 2012. Using the data collection
instrument, we gathered data on sociodemographic character-
istics, diagnosis, ablation performed, health outcomes of the
procedure (success and complication rates), number of follow-
up visits a year, MT undertaken, and recurrence of the arrhyth-
mia at 5 months and a year after the procedure (Table 1).
A total of 269 patients participating in the electrophysiology
study were identiﬁed (Fig. 1). Of these patients, 137 were pediatric
cases and an additional 29 of the remaining 132 adults were
excluded. The ﬁnal sample was 103 patients. The patients’
demographic characteristics are presented in Table 1.
Decision Model Development
Using the available literature and the outcomes and demographic
data of the remaining 103 patients, we developed a decision tree
using Microsoft Excel 2013. To create the model, we generated a
hypothetical group of patients who underwent either MT or RFA.
Patients entered a therapy-speciﬁc subtree that simulated the
probability of success, recurrence of the SVT after the initial
treatment, and complication rates. The patients were considered
to initiate in one arm of the tree and move forward at the next
appointment 1 year later. If the treatment was not successful,
Patients in whom EPS was 
performed
269
Pediatric EPS
137
Adult EPS
132
Excluded
29
File not 
available
6
Short PR interval 
(preexitation) with 
normal EPS
2
Ventricular 
tachycardia
8
Repeated EPS and 
ablation (only 
considered once)
13
Total 
Included
103
Fig. 1 – Patient population. Distribution of study patients
included in whom EPS was performed from August 2007 to
April 2012. Follow-up appointment and cardiac rhythm by
EKG were evaluated until April 2013 to ensure no recurrence
of the SVT. EKG, electrocardiogram; EPS, electrophysiological
study; SVT, supraventricular tachycardia.
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new medication or undergoing RFA). By the end of the second
year of the model, patients were considered stable in the treat-
ment category they remained and the costs were calculated on
the basis of this (Fig. 2).
We used the local data of the RFA procedure, when possible,
to include the probability of occurrence, complications, cost,
and quality of life associated with that outcome. If the proba-
bility for an event in the model was not observed in local
outcomes (e.g., mortality), it was extrapolated from the pub-
lished literature (Table 2), mainly from the studies of Hogenhuis
et al. [7], Cheng et al. [8], Calkins et al. [9], Ikeda et al. [10], and
Bathina et al. [11].
Utilities were primarily extrapolated from values used by
Cheng et al. [8] and Larson et al. [12] in their analyses. Larson
et al. [12] obtained the utility retrospectively by evaluating highly
symptomatic patients with SVT, so we considered it to be the
best data for the utilities in our analysis. We assumed that the
complications of hemodynamic instability, major bleeding, and
vascular injury were transient and were considered resolved
before the discharge. Patients who were assumed to get complete
heart block had quality of life associated with pacemaker
placement.Paent 
with SVT
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Success 
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Follow Up
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ig. 2 – Decision tree. Patients entered a therapy-speciﬁc subtree
he SVT after the initial treatment. All the nonfatal complications
adiofrequency ablation; SVT, supraventricular tachycardia.We considered a 35-year time frame because that is our
sample’s average age subtracted from Guatemala’s life expectancy.
Medical treatment
Patients under drug therapy were assumed to receive a daily dose
of propafenone. Although we recognized that more inexpensive
drugs might be used in actual practice, our choice for the model
was propafenone because most of the patients use this drug in
UNICAR. Of every 100 patients in the MT arm, 60% would have a
reduction in symptoms with MT [7,8,13–15], 10% would need a
second drug for their symptoms to be controlled, and 30% would
enter the ablation arm of the model. The episodic drug therapy
(pill-on-the-pocket strategy) was not included because it has
been proven in previous studies to be inferior to long-term drug
therapy for highly symptomatic patients [8]. The adverse effects
of medications reduced the quality of life for patients.
We did not include emergency department visits in neither
strategy because UNICAR does not offer that service.
Radiofrequency Ablation
We deﬁned RFA as initially successful if the electrophysiologist
could not induce an arrhythmia in the laboratory after the RFA.
However, some patients in whom RFA is initially successful
subsequently experience recurrent SVT, typically in the ﬁrst few
weeks after the procedure [8]. In the model, the patient visited
the clinic twice the ﬁrst year after the procedure to ensure that
there was no recurrence. Patients were also switched to the MT
arm if the arrhythmia was not ablatable or if the ablation was
unsuccessful.
Efﬁcacy and complications
The efﬁcacy and complication rates were extrapolated from
outcomes in UNICAR. Of the patients assigned to the RFA arm,
83.48% were presumed to have a successful ablation, 16.49% to
have a failed ablation, and 0.03% to have a fatal outcome.
Regardless of the ablation success, 1.96% were estimated to have
a nonfatal complication.
We assumed that patients in whom RFA was successful
required no further antiarrhythmic medication. The incremental
costs for each of the complications are described in the footnote
of Table 2. A major bleeding episode was deﬁned as an episode
greater than type 3 bleeding in the deﬁnition proposed
by Meheran et al. [16], including those that required blooda
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that simulated the probability of success and recurrence of
were considered in patients with successful ablations. RFA,
Table 2 – Inputs used in the decision tree.
Probabilities of follow-up events Base case Utility [8,12] Source—Reference
Patients going on chronic MT
Success with ﬁrst drug (propafenone) 60.00% 0.833 [7,8,10,12,14,15]
Success after second drug 10.00% 0.833 Expert consensus [10,12]
MT fails, goes to RFA 29.00% 0.983 Expert consensus [8,12]
Patients entering RFA
Success after ﬁrst ablation 83.48% 0.983 Outcomes in UNICAR [8,10,12]
Recurrence after ﬁrst ablation 16.49% Outcomes in UNICAR [8,12]
MT after recurrence 4.85% 0.833 Outcomes in UNICAR [8,11,12]
Second ablation after recurrence 11.64% Outcomes in UNICAR
Success reached after second ablation 10.67% 0.983 Outcomes in UNICAR
MT after second ablation 0.97% 0.833 Outcomes in UNICAR
Procedural complications Base case Utility [8,12] Source—Reference
Death 0.030% 0 UNICAR [7,9, 10, 12,18]
Nonfatal complications 1.96% (0.015%–3.0%) UNICAR [7,9–12]
Complete heart block 0.49% 0.776 UNICAR [7,9–12]
Hemodynamic instability 0.49% 0.933 UNICAR [7,9–12]
Major bleeding 0.49% 0.933 UNICAR [7,9–12]
Vascular injury 0.49% 0.933 UNICAR [7,9–12]
Considerations Base case Utility [8,12] Source—Reference
Patient appointments during the year of RFA 2 Outcomes in UNICAR
Patient outpatient appointments/y after RFA 1 Outcomes in UNICAR
Patient outpatient appointments/y after MT 2 Outcomes in UNICAR
Time horizon (y) 35
Inﬂation rate 6%
Discount rate 12%
Days in ICU for complete heart block 1 Outcomes in UNICAR
Days in ICU for hemodynamic instability 3 Outcomes in UNICAR
Days in ICU for major bleeding 2 Outcomes in UNICAR
Days in ICU for vascular injury 1 Outcomes in UNICAR
Frequency of pacemaker replacement (y) 8 Outcomes in UNICAR
Cost ($) Base case Utility [8,12] Source—Reference
Ablation procedure* 5411.08 UNICAR’s administration
Floor hospitalization† 340.22 UNICAR’s administration
ICU day 606.16 UNICAR’s administration
Bicameral pacemaker placement 2355.85 UNICAR’s administration
Outpatient appointment‡ 44.46 UNICAR’s administration
Incremental cost of procedural complications
Complete heart block§ 2962.01 UNICAR’s administration
Hemodynamic instability|| 1818.48 UNICAR’s administration
Major bleeding¶ 1325.73 UNICAR’s administration
Vascular injury# 719.57 UNICAR’s administration
Yearly follow-up on MT
Transport 11.00
Yearly treatment with propafenone 992.31 UNICAR’s administration
Yearly propafenone þ amiodarone 1249.23 UNICAR’s administration
EKG, electrocardiogram; ICU, intensive care unit; MT, medical treatment; RFA, radiofrequency ablation; UNICAR, Unidad Nacional de Cirugía
Cardiovascular.
* Basic cost includes ablation procedure.
† Includes ﬂoor bed (1 d), one EKG, analgesic postprocedure, gastric protection with H2-blocker
‡ Includes salaries of personnel and one EKG.
§ Includes 1 d in ICU, placement of bicameral peacemaker, two appointments per year, exchange of device every 8 y.
|| Includes 3 d in ICU.
¶ Includes 2 d in ICU care and 1 more day of ﬂoor stay.
# Includes one more ﬂoor night and 1 d in ICU.
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cardiac tamponade, intracranial bleeding, or fatal bleeding.
Hemodynamic instability was deﬁned as persistent hypotensiondespite ﬂuid management. If the probability for an event in the
model was not observed in the local outcomes (e.g., mortality), it
was extrapolated from the published literature (Table 2).
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arm) 29.41% were estimated to enter MT (4.85% of the total
fraction in the RFA arm) and the remainder had a second
ablation. A total of 91.67% of the second ablations were success-
ful, leading to a total success rate of 94.15% after two ablations.
We assumed that the remainder who failed the second ablation
had MT.
Costs
We calculated all the costs on the basis of data from UNICAR’s
administration during 2012. The data were provided in the local
currency (quetzales), which had a conversion factor of US $1 ¼
7.8Q in 2012. The basic cost of the RFA was $5411.08, and the
costs for each arm of the tree were calculated from this. To
calculate the follow-up costs, we assumed two outpatient follow-
up visits in the ﬁrst year and then one outpatient appointment
for patients in the RFA arm (except for patients with complete
heart block who get two yearly appointments) and two appoint-
ments for those in the MT arm. The cost of each appointment
was calculated by including the salary of physicians and nurses,
the cost of one electrocardiogram, and the cost of transport of the
patient to UNICAR. We estimated an annual inﬂation rate of 6%,
using the average inﬂation rate in the last 20 years in Guatemala.
The costs were discounted at a 12% nominal discount rate per
year (6% real discount rate) because in the context of Guatemala
that is a conservative rate. The discount and inﬂation rates were
tested in sensitivity analysis.
Cost-Effectiveness Analysis
Therapies for non–life-threatening SVT by deﬁnition affect qual-
ity of life rather than length of life [8]. Because of this, we used
QALYs to measure the effect of our model.
In this methodology, different states of health can be asso-
ciated with differences in quality of life (utilities). The utilities
assess how patients value health states and typically range from
0 (representing death) to 1 (representing ideal health). Utilities
differ from measures of functional status in that they assess how
much health state bothers patients rather than describing the
health state in terms of what patients can do. We assigned a
“quality of life” for each state of health in the decision tree to
reﬂect those utilities for each possible outcome [7,16]. Patients
remaining in the well state for 1 year (utility of 1) were credited
with one QALY, dead patients were credited with zero QALY, and
patients experiencing morbidity accumulated life-years at an
intermediate rate.
Discounting
We considered that each patient entering the model would
live an additional 35 years, which is the average life expectancy
of Guatemalans minus the average age at ablation. We calculated
the expenses incurred in those 35 years of each arm of the
model and applied the concept of present value of future
expenses. More details about discounting are presented in theTable 3 – Cost-effectiveness analysis.
Total
QALYs
Total
undiscounted
cost ($)
Total
undiscounted
QALYs
Discounted
costs ($)
Disco
QA
MT 103,385.66 30.73 16,460.21 1
RFA 19,658.33 34.05 8,466.76 1
ICER, incremental cost-effectiveness ratio; MT, medical treatment; QALYAppendix in Supplemental Materials found at http://dx.doi.org/
10.1016/j.vhri.2015.06.002.
Decision analysis, projections, and sensitivity analysis
We calculated the expected costs and QALYs per patient treated
medically or with RFA for SVT. We then calculated the incre-
mental cost-effectiveness ratio for RFA versus MT and calculated
the net beneﬁt of each intervention. The net beneﬁt is a dollar
value encompassing the ﬁnancial and health value of the inter-
vention (see details in the Appendix in Supplemental Materials).
Finally, we performed one-way and probabilistic sensitivity
analyses on the input parameters to determine which variables
had the largest impact on the results. The probabilistic sensitivity
analysis was conducted with 10,000 iterations using input dis-
tributions presented in Appendix Table A.4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.06.002.Results
Local Outcomes in UNICAR
Table 1 presents the characteristics of study patients. There was
an overall success rate of 83.48% with a ﬁrst RFA and a cumu-
lative success rate of 94.15% after a second RFA
Costs
On the basis of data available at UNICAR, we calculated the basic
cost of RFA at $5411.08. The details of expenses for each of the
arms are explained in the footnote of Table 2. Because of long-
term medications, the MT arm had $16,460 in discounted costs
over 35 years. Although RFA had higher initial costs and some
costs of complications, longer-term costs were lower because
patients took fewer medications. The expected 35-year dis-
counted costs of RFA were $8467. Appendix Figure A.1 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.vhri.2015.06.
002 shows the cumulative average cost of RFA versus MT.
Calculation of QALYs
Patients with successful RFA had improved quality of life. Table 3
presents expected outcomes under MT and RFA. Patients with MT
had 13.49 expected discounted QALYs over 35 years, whereas
patients with RFA had 14.95 discounted QALYs over the same
time period. There was a gain of 1.46 QALYs and a saving of $7993
with RFA compared with MT, which represents a saving of $5480
per QALY gained. This demonstrates that RFA dominates MT in
the management of SVT.
We calculated the net beneﬁt using the formula described in
the Appendix in Supplemental Materials to examine the dollar
value of the choice of therapy. This represents how much one
might be willing to pay to have RFA instead of MT if one values
QALYs at $3478 (per-capita GDP of Guatemala) over a 35-year
time frame. If QALYs are valued at that amount, then RFAunted
LYs
ICER ($) Dominance Net
beneﬁt
($)
Incremental
dollar beneﬁt
of RFA vs. MT
($)
3.49 Dominated 30,469
4.95 5,480.24 Dominant 43,536 13,066
; quality-adjusted life-year; RFA, radiofrequency ablation.
 $-  $5,000  $10,000  $15,000  $20,000  $25,000
Probability of success aer second drug
Probability of geng medical treatment,…
Yearly cost of propafenone + amiodarone
Probability of success given 2nd ablaon
Cost of ablaon procedure
Probability of success aer ﬁrst ablaon
Inﬂaon rate
Yearly treatment cost with propafenone
Probability of success with ﬁrst drug
Discount rate
Net Monetary Beneﬁt of RFA over MT
Fig. 3 – Sensitivity analysis. Tornado diagram displaying the results of key one-way sensitivity analyses on the change in net
monetary beneﬁt of RFA over MT. The vertical dotted line represents $13,066, the base-case incremental value of RFA over MT.
MT, medical treatment; RFA, radiofrequency ablation.
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of cost savings and health improvement.
We plotted the incremental cost-effectiveness ratio per year
to observe the trend of cost-effectiveness in each year after the
procedure (see Appendix Fig. A2 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2015.06.002).
Sensitivity Analysis
In addition to our base-case analyses, we performed one-way and
probabilistic sensitivity analyses (see Appendix Table A4 in
Supplemental Materials) in which we systematically varied
parameters between low and high values [8].
Fig. 3 presents a tornado diagram displaying the results of key
one-way sensitivity analyses on the net beneﬁt of RFA compared
with MT. The base-case incremental value of RFA over MT is $13,066.
Varying individual parameters within 20% (or extreme limits, if 20%
was not possible) show the incremental value of RFA over MT in the
horizontal bars. The net monetary value varies slightly, but RFA still
always has a positive net monetary value over MT.
The probabilistic sensitivity analysis showed that RFA is
highly likely to be cost-effective. There is a 78% chance of it
being cost saving and a 92% chance of having a cost-effectiveness
ratio of less than $3500 per QALY. Cost-effectiveness acceptability
curves are shown in Figure A3.Discussion
In the present study, we used a disease simulation model to
project cost and quality-adjusted life expectancy for a population
of 35-year-old patients with symptomatic SVT who were treated
with either RFA or continued MT. Using assumptions based
largely on the outcomes in UNICAR, we found that RFA is highly
cost-effective, taking as a reference the guidelines of World
Health Organization-CHOosing Interventions that are Cost Effec-
tive (o1 GDP per capita) [9,17].
In Guatemala, the mean cost per RFA of SVT was $5411.08,
which is cheaper than that reported in other studies from devel-
oped nations, such as Australia, Japan, and the United States
[4,7,10,17]. Even when including the costs of the second RFA (after
an unsuccessful ﬁrst attempt; 94.2% success rate), the cost still
proved to be between 68.4% and 90.3% lower than that reported in
other countries [4,7,10,11]. This lower cost is due to the much lower
salaries of medical, nursing, and technical personnel in Guatemala.
In addition, the use of resterilized material, such as ablation
catheters, decreases the overall cost of the procedure by 66% [4].When compared with the long-term costs of MT, RFA was almost
$8000 less expensive. This indicates that our results are congruent
with those of previous studies, including one from Guatemala in
the pediatric population, showing that RFA dominates MT for the
management of SVT, even in different contexts and with different
assumptions [3,4,7,8,11,13].
The model we developed predicts that in patients with SVT,
RFA yields a quality-adjusted life expectancy greater than that
yielded by MT. Our ﬁndings support the usual international
practice of initially performing RFA in patients with highly
symptomatic SVT. This beneﬁt overcomes the low risk of mortal-
ity or nonfatal complications during the procedure.
Our analysis conﬁrms the ﬁnancial beneﬁts of RFA, partic-
ularly with long-term follow-up, due to the elimination of anti-
arrhythmic medications and the avoidance of subsequent
intensive care unit and hospital stays for SVT recurrences.
According to our results, RFA proved effective for patients
with drug-refractory symptoms as well as frequent arrhythmic
episodes requiring medical attention. Appendix Figure A2 in
Supplemental Materials shows that RFA becomes cost-effective
from the second year (incremental cost-effectiveness ratio o3
times the GDP), highly cost-effective from the fourth year (othe
GDP), and cost saving from the seventh year. This is even after
considering a second ablation for those in whom it failed the ﬁrst
time and those who develop any complication. RFA remained the
dominant strategy even after we performed probabilistic and
deterministic sensitivity analysis, even with a decrease of 50% in
the cost of medications. This suggests that RFA, especially in low-
income countries, should be the most appropriate therapeutic
choice, especially in young patients who would otherwise require
lifelong MT [11]. RFA is either cost saving or has a cost-
effectiveness ratio comparable to that of many commonly
accepted therapies for other diseases [7].
Our sensitivity analyses indicate that RFA is likely to be cost
saving or cost-effective under a wide range of assumptions. We
made several assumptions to produce a tractable model. We used
a long-term perspective to consider in more detail the cost and
risk associated with the strategies. Prolonged drug therapy leads
to both increased expenditures and an increased risk of adverse
effects. We also explicitly modeled crossovers between therapies.
RFA is considered a safe procedure. No deaths were included
in the second ablation because it has not been found in previous
analysis [4] or it has been signiﬁcantly lower (0.016% [7], 0.05%
[11], and 0.001% [18]) than the 0.03% assumed for our model. We
acknowledge that resterilization is a suboptimal and unconven-
tional procedure to lower costs despite the fact that our experi-
ence shows no increase in complication rates [4].
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 9 2 – 9 898The high interest rates for loans taken from the banking system
and eventual currency devaluation make the 12% discount rate
that we used a conservative rate. It is important to realize that
most US studies have used a discount rate of 3% because of a more
stable economic system in the United States [8].
This model has several limitations. Because our institution does
not possess the information needed to calculate the cost of every
single medication used in the electrophysiology study, we included
the information provided by the UNICAR administration using
hypothetical patients who underwent catheter ablation and infor-
mation about the most commonly prescribed drugs. Because this
may not always be the case, costs might be underestimated (even
though this would represent o5% of the total cost of the proce-
dure). Another limitation relates to the fact that before patients
were referred to our unit they were treated by various cardiologists
without a standard antiarrhythmic protocol [4]. Furthermore, we
are not including other comorbidities in the 35-year time frame that
could have decreased the QALYs of a given patient.
The fact that we did not include emergency department treat-
ment in our model because it is not offered in UNICAR does not
necessarily mean that the patient did not require such treatment
(and expenditure) in case of a recurrence of the arrhythmia. If MT
patients were to require emergency department treatment, RFA
would have an even larger decrease in expenditures.Conclusions
Our study found that RFA dominates MT by improving quality of
life and reducing expenditures when used to treat patients with
severe symptoms. This is a constant ﬁnding, even after varying
assumptions about efﬁcacy, complication rates, and quality of life
of patients after RFA. Although this analysis used data from
Guatemala, the robustness of the results to variations in param-
eter assumptions suggests that the insights from this study may
also hold for other low-income countries with similar costs and
procedures.
Given our ﬁndings, it may be cost-effective to allocate resour-
ces in low-income countries to develop facilities specialized in
cardiac electrophysiology to treat effectively, deﬁnitively, and at
lower cost patients with SVT. We recommend continued testing
of the cost-effectiveness of high-technology therapies in devel-
oping countries and different settings because the different
experience of the teams, cultural acceptance, and lower costs
can provide results different from those in developed countries.Acknowledgments
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